WHITNEY WASHINGTON: Open Payments
NPI 1063005718 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,496 in 129 payments from 37 companies in 2025. Trend: 2023 $859 · 2024 $2,050 · 2025 $3,496
Food & beverage: $3,496
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 15 | $336 |
| Genentech USA, Inc. | 11 | $254 |
| Novartis Pharmaceuticals Corporation | 9 | $246 |
| GlaxoSmithKline, LLC. | 10 | $241 |
| AstraZeneca Pharmaceuticals LP | 8 | $184 |
| Merck Sharp & Dohme LLC | 7 | $172 |
| E.R. Squibb & Sons, L.L.C. | 4 | $142 |
| Astellas Pharma US Inc | 6 | $138 |
| Daiichi Sankyo Inc. | 5 | $131 |
| ViiV Healthcare Company | 1 | $125 |
Products named: Itovebi, OPDIVO, ENHERTU, XTANDI, KEYTRUDA, TALVEY, RYBREVANT, JEMPERLI.
Industry payments across LA — which companies pay providers there.
